Creating a delivery method for COVID-19: Monoclonal antibody therapy

Ashley Deford
*Advocate Aurora Health, ashley.deford@aah.org*

Annette Coates
*Advocate Aurora Health, annette.coates@aah.org*

Follow this and additional works at: [https://institutionalrepository.aah.org/nurs](https://institutionalrepository.aah.org/nurs)

**Recommended Citation**
Creating a Delivery Method for COVID-19
Monoclonal Antibody Therapy
Introduction

▪ U.S. Food and Drug Administration issued an Emergency Use Authorization to permit the use of Sotrovimab for COVID-19

▪ Monoclonal antibody (mAb) therapy provided treatment for mild-to-moderate COVID-19 disease

▪ Operational leadership and clinical informatics collaborated to create a mAb infusion program

▪ Evaluated eligibility requirements and medication availability
Rationale

- mAb infusion program provided patients with accessibility to COVID-19 treatment
- Prevented progression from mild-to-moderate COVID-19 to severe disease
- Diminished the need for hospitalization and utilization of resources
- Minimized the spread of COVID-19 disease in the community

(Sakata et al., 2021)
Method: Collaboration

- Collaborative partnership (with Nursing, Pharmacy, Patient Access, Physicians, Health Information Management and Clinical Informatics)
  - Operational Support
  - Business Service Request
  - Staffing
  - Epic
    - Access
    - Sotrovimab Therapy Plan
    - Appointment Scheduling
    - Training
    - On-Site Support
Method: mAb Therapy

- Precautions
- Vital signs
- IV access
- Documentation
- Medication infusion
- Charge capture
- Discharge instructions
Results & Findings

- Number of Patients who received COVID mAb Therapy at Good Shepherd:

  - **January:** 108
    - Admissions: 5
    - Ventilators: 1
  
  - **February:** 54
    - Admissions: 4
    - Ventilators: 0
  
  - **March:** 46
    - Admissions: 3
    - Ventilators: 0
  
  - **April:** 32
    - Admissions: 6
    - Ventilators: 0
Discussion & Conclusions

- Patients who received mAb therapy at Good Shepherd:
  - Reduced the need for ventilators
  - Reduced the need for inpatient admissions

- Further data analysis is required to understand:
  - If mAb therapy reduces the number of deaths
  - If mAb therapy causes any severe side effects
  - How COVID-19 variants impact the efficacy of mAb therapy

- Future considerations

(Kreuzberger et al., 2021)
Implications for Practice

- Rapid development of COVID-19 mAb Infusions Departments can be created with intra-department collaboration.

- Patients with mild-to-moderate COVID-19 infection can benefit from mAb therapy by preventing inpatient admissions and ventilator needs.